74.02
4.37%
+3.10
After Hours:
74.02
Overview
News
Price History
Option Chain
Why RDY Down?
Discussions
Forecast
Stock Split
Dividend History
Dr. Reddy's Laboratories Ltd. ADR stock is currently priced at $74.02, with a 24-hour trading volume of 218.14K.
It has seen a +4.37% increased in the last 24 hours and a +0.83% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $71.11 pivot point. If it approaches the $72.29 resistance level, significant changes may occur.
Previous Close:
$70.92
Open:
$73.4
24h Volume:
218.14K
Market Cap:
$12.33B
Revenue:
$3.29B
Net Income/Loss:
$632.08M
P/E Ratio:
19.93
EPS:
3.7138
Net Cash Flow:
$359.06M
1W Performance:
+4.39%
1M Performance:
+0.83%
6M Performance:
+11.96%
1Y Performance:
+24.89%
Dr. Reddy's Laboratories Ltd. ADR Stock (RDY) Company Profile
Name
Dr. Reddy's Laboratories Ltd. ADR
Sector
Phone
91 40 4900 2900
Address
8-2-337, Road No. 3, Banjara Hills, Hyderabad
Dr. Reddy's Laboratories Ltd. ADR Stock (RDY) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-11-24 | Downgrade | Jefferies | Buy → Underperform |
Aug-29-23 | Downgrade | HSBC Securities | Buy → Hold |
May-18-23 | Downgrade | Bernstein | Outperform → Mkt Perform |
Mar-17-23 | Upgrade | BofA Securities | Neutral → Buy |
Jan-30-23 | Initiated | JP Morgan | Underweight |
Nov-14-22 | Downgrade | Credit Suisse | Neutral → Underperform |
Jan-03-22 | Resumed | BofA Securities | Neutral |
Jul-27-21 | Downgrade | Credit Suisse | Outperform → Neutral |
Feb-02-21 | Upgrade | Barclays | Equal Weight → Overweight |
Sep-18-20 | Upgrade | BofA Securities | Neutral → Buy |
Sep-18-20 | Upgrade | Investec | Sell → Hold |
Jan-28-20 | Downgrade | CLSA | Buy → Outperform |
Jan-27-20 | Downgrade | CLSA | Buy → Outperform |
Jan-09-20 | Upgrade | Citigroup | Sell → Buy |
Nov-04-19 | Downgrade | BofA/Merrill | Buy → Neutral |
Sep-04-19 | Upgrade | Credit Suisse | Underperform → Outperform |
Jul-01-19 | Upgrade | Macquarie | Neutral → Outperform |
Jun-20-19 | Initiated | Deutsche Bank | Hold |
Jun-11-19 | Initiated | Barclays | Equal Weight |
May-20-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Feb-19-19 | Upgrade | CLSA | Outperform → Buy |
Jan-17-19 | Downgrade | Citigroup | Neutral → Sell |
Sep-21-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Aug-31-17 | Upgrade | CLSA | Underperform → Outperform |
Jul-28-17 | Downgrade | CLSA | Underperform → Sell |
Jul-27-16 | Downgrade | HSBC Securities | Hold → Reduce |
Jul-27-16 | Downgrade | Jefferies | Hold → Underperform |
Feb-10-16 | Upgrade | Credit Agricole | Underperform → Buy |
Nov-10-15 | Downgrade | Citigroup | Buy → Neutral |
View All
Dr. Reddy's Laboratories Ltd. ADR Stock (RDY) Latest News
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris
Zacks Investment Research
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
Zacks Investment Research
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Zacks Investment Research
Here's Why Doctor Reddy's (RDY) is a Strong Value Stock
Zacks Investment Research
Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term
Zacks Investment Research
Here's Why Doctor Reddy's (RDY) is a Strong Momentum Stock
Zacks Investment Research
Dr. Reddy's Laboratories Ltd. ADR Stock (RDY) Financials Data
Dr. Reddy's Laboratories Ltd. ADR (RDY) Revenue 2024
RDY reported a revenue (TTM) of $3.29 billion for the quarter ending December 31, 2023, a +9.01% rise year-over-year.
Dr. Reddy's Laboratories Ltd. ADR (RDY) Net Income 2024
RDY net income (TTM) was $632.08 million for the quarter ending December 31, 2023, a +38.34% increase year-over-year.
Dr. Reddy's Laboratories Ltd. ADR (RDY) Cash Flow 2024
RDY recorded a free cash flow (TTM) of $359.06 million for the quarter ending December 31, 2023, a -0.79% decrease year-over-year.
Dr. Reddy's Laboratories Ltd. ADR (RDY) Earnings per Share 2024
RDY earnings per share (TTM) was $3.794 for the quarter ending December 31, 2023, a +38.13% growth year-over-year.
About Dr. Reddy's Laboratories Ltd. ADR
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations for dermatology and neurology therapeutic areas. It also provides a portfolio of in-licensed dermatology products. As of March 31, 2018, this segment had 13 active products development programs pipeline that are in various stages of development. The company's therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, pain management, oncology, dermatology, urology, and nephrology. It has collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology; and collaboration agreement with Merck Serono to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. Dr. Reddy's Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.
Cap:
|
Volume (24h):